19 articles, transcripts, and reports
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q2 2025 Earnings Call dated Aug. 04, 2025 Corporate Participants: Susie Lisa — Senior Vice President, Investor Relations Reshma Kewalramani…
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q3 2025 Earnings Call dated Nov. 03, 2025 Corporate Participants: Susie Lisa — Senior Vice President, Investor Relations Reshma Kewalramani…
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported product revenue of $2.49 billion for the second quarter of 2023, which was up 14% year-over-year. Net income was $915.7…
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported total revenues of $2.3 billion for the fourth quarter of 2022. This compares to $2 billion in the same period…
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q4 2022 earnings call dated Feb. 07, 2023 Corporate Participants: Susie Lisa — Senior Vice President, Investor Relations Reshma Kewalramani — Chief Executive Officer…
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q3 2022 earnings call dated Oct. 27, 2022 Corporate Participants: Susie Lisa — Senior Vice President, Investor Relations Reshma Kewalramani — Chief Executive Officer…
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q4 2021 earnings call dated Jan. 26, 2022 Corporate Participants: Michael Partridge — Senior Vice President of Investor Relations Reshma Kewalramani — Chief Executive…
Biotechnology company Vertex Pharmaceuticals (NASDAQ: VRTX) has reported higher earnings and revenues for the third quarter of 2021. The bottom line also exceeded Wall Street’s…
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q1 2021 earnings call dated Apr. 29, 2021 Corporate Participants: Michael Partridge — Senior Vice President of Investor Relations Reshma Kewalramani — Chief Executive…
After dominating the cystic fibrosis market for quite some time, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is currently expanding its clinical programs to other diseases. While…
